Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Non-cash Items (2017 - 2025)

Spero Therapeutics (SPRO) has disclosed Non-cash Items for 9 consecutive years, with $20.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-cash Items rose 698.34% year-over-year to $20.9 million, compared with a TTM value of $20.9 million through Sep 2025, up 698.34%, and an annual FY2023 reading of $1000.0, changed 0.0% over the prior year.
  • Non-cash Items was $20.9 million for Q3 2025 at Spero Therapeutics, up from $2.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $24.3 million in Q4 2021 and bottomed at $1000.0 in Q4 2022.
  • Average Non-cash Items over 5 years is $5.1 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Non-cash Items tumbled 100.0% in 2022, then surged 261444.0% in 2024.
  • Year by year, Non-cash Items stood at $24.3 million in 2021, then crashed by 100.0% to $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023, then soared by 261444.0% to $2.6 million in 2024, then skyrocketed by 698.34% to $20.9 million in 2025.
  • Business Quant data shows Non-cash Items for SPRO at $20.9 million in Q3 2025, $2.5 million in Q2 2025, and $2.6 million in Q3 2024.